The latest announcement is out from MaxCyte ( (MXCT) ).
MaxCyte, Inc. announced its intention to cancel the admission of its common stock from trading on the AIM market of the London Stock Exchange, subject to stockholder approval, while maintaining its listing on the Nasdaq Global Select Market. The decision is driven by the fact that over 94% of trading occurs on Nasdaq, and the company aims to enhance liquidity and reduce costs associated with dual listings. The board believes the AIM Delisting aligns with the company’s strategic objectives, having already achieved significant growth and market expansion through its AIM Admission.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell-engineering industry, providing platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics. The company focuses on enabling cell therapy advancements and has a significant presence in the U.S. market.
YTD Price Performance: -41.36%
Average Trading Volume: 31,102
Technical Sentiment Signal: Strong Buy
Current Market Cap: £208.7M
For a thorough assessment of MXCT stock, go to TipRanks’ Stock Analysis page.